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Background: Many composite disease activity measures and targets have been developed for 
psoriatic arthritis (PsA). This GRAPPA-OMERACT work stream aimed to further the development of 
consensus among physicians and patients.  
 
Methods: Prior to the meeting, physicians and patients were surveyed on outcome measures. A 
consensus meeting (26 rheumatologists, dermatologists, and patient representatives) reviewed 
evidence on composite measures and potential treatment targets, plus survey results. After 
discussions, participants voted on proposals for use and consensus was established in a second 
survey.  
 
Results:  
Survey results from 128 HCPS and 139 patients were analysed alongside a SLR summarising 
evidence.  A weighted vote was cast for composite measures (for RCTs, most popular measures were 
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PASDAS [40 votes] and GRACE [28 votes]; for clinical practice, most popular were 3-VAS [45 votes], 
DAPSA [26 votes]). After discussion there was no consensus on a composite measure. The group 
agreed that several composite measures could be used. Future studies should allow further 
validation and comparison. 
 
The group unanimously agreed that remission should be the ideal target with minimal/low disease 
activity a feasible alternative. The target should include assessment of musculoskeletal disease, skin 
and health related quality of life.  The group recommended a target of treatment as VLDA, or MDA. 
 
Conclusions: Consensus was not reached on a continuous measure of disease activity.  In the interim 
the group recommends several composites.  Consensus was reached on a treatment target of 
VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA 
clinical domains be collected in ongoing studies.  
 
Introduction 
In 2016, a new core outcome set for psoriatic arthritis (PsA) was developed by the Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) group and endorsed by the 
Outcome Measures in Rheumatology Clinical Trials (OMERACT) conference(1).  This was the result of 
a two year programme of work to establish the key domains for randomised controlled trials (RCTs) 
and observational studies in PsA.  Following acceptance of this core outcome set, the 
GRAPPA/OMERACT group is developing the complementary core outcome measurement set which 
will recommend outcome measures to assess these domains in PsA. 
Different groups have been established to examine groups of outcome measures including patient 
reported outcomes, musculoskeletal disease activity, skin disease activity, systemic inflammation, 
imaging, economic cost and composite disease activity measures.  Composite disease activity 
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measures most commonly focus on disease activity and are frequently used in RCTs and increasingly 
in routine practice to assess outcomes of therapy in PsA and other inflammatory arthritides.  Whilst, 
by definition, composite measures include multiple components, they can vary significantly in terms 
of the domains addressed and methods used to combine them into a composite score. 
Nearly all composite disease activity measures combine patient reported outcomes (eg pain, patient 
global) with physician assessed outcomes (eg joint counts, body surface area of psoriasis).  
Historically, the composite measures used for PsA have been developed in other diseases, most 
commonly rheumatoid arthritis, and focus specifically on peripheral arthritis as a single domain.  
More recently newer composites have been developed specifically for PsA which have combined 
outcome measures in multiple domains (eg peripheral arthritis, skin psoriasis, enthesitis) into a 
single composite to reflect all of the ways a patient may be affected by their psoriatic disease 
activity. 
The objective of this work was to use multiple methodologies to review composite measures and 
potential treatment targets in PsA establishing recommendations and developing a research agenda 
for future work.  This paper reports the output of a consensus meeting, with discussions focusing on 
the systematic literature review data and pre and post meeting surveys of patients and physicians 
held in 2017. 
 
Methods 
Prior to the consensus meeting, two surveys were conducted.  One survey was sent to health care 
professional (HCP) members of GRAPPA to establish current practice internationally with regard to 
composite measures and targets.  A second survey was sent to patients with PsA to establish their 
experience, what assessments they feel are important and how they wish to be involved.  Patients 
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were recruited internationally including several GRAPPA patient research partners (PRPs), members 
of patient support groups and patients recruited from routine clinics. 
As part of the GRAPPA-OMERACT initiative, a systematic literature review (SLR) of composite disease 
activity measures was undertaken, alongside other groups reviewing patient reported outcomes, 
clinical disease activity measures, laboratory and imaging measures.  The first part of this initiative 
was a systematic literature review to identify all composite measures tested in PsA and to assess 
their validity in this disease.  Using data identified and summarised for the SLR, evidence sheets for 
the composite measures and potential targets were developed for the consensus meeting 
attendees.  Two different versions were created, one for physicians and one for PRPs.  These 
summarised the level of evidence for the measures using the OMERACT filter(2). 
On 10th February 2017, a one day consensus meeting was held. The meeting had an independent 
chairperson (AMK) and consisted of plenary presentations, breakout groups, group discussion and 
voting. International experts including members of GRAPPA and OMERACT were invited to the 
consensus meeting, including the developers of all of the measures discussed.  Both rheumatologists 
and dermatologists were invited to ensure that both musculoskeletal and skin manifestations of PsA 
were considered, and four PRPs from GRAPPA were invited to ensure representation of the patient 
perspective.  At the meeting, key data including results of the pre-meeting surveys were presented. 
The morning session of the consensus day was focused on composite measures of disease activity in 
PsA.  The composite measures discussed were PsA disease activity score (PASDAS)(3), GRAPPA 
composite index (GRACE)(3), composite psoriatic disease activity index (CPDAI)(4), disease activity in 
PsA (DAPSA)(5), routine assessment of patient index data 3 (RAPID3)(6) and 3 visual analogue scales 
(VAS) scores (3-VAS: patient global, patient skin and physician global).   
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The afternoon session focused on treating to target and potential targets available in PsA.  These 
included cut points of these composite measures where available but focussed specifically on DAPSA 
remission/low disease activity(7), the minimal disease activity (MDA) criteria(8) and more stringent 
very low disease activity (VLDA)(9) as these two measures had accumulated the most validation 
data.  The domains included in these composite measures are shown in Table 1. 
For both sessions, after presentation of the key data for the outcome measures, breakout groups 
with representatives from rheumatology, dermatology and PRPs were established to discuss the 
pros and cons for each measure.  These groups then reported back to the complete attendee group.  
There was then discussion and debate on the different measures with voting on recommendations. 
Results 
Composite disease activity measures 
Physician survey – A total of 128 health care professionals responded, the majority (82%) 
rheumatologists.  The domains of disease most commonly assessed in clinical practice were joints 
(97%), dactylitic digits (88%), entheses (87%), pain (86%), CRP/ESR (86%) and skin (84%).  When 
asking specifically about composite measures, 45% of HCPs reported that they regularly use a 
composite measure in their practice, most commonly the minimal disease activity (MDA) or the 
routine assessment of patient index data (RAPID3).  The majority of respondents thought that a 
single composite measure was more clinically useful than individual assessment of each domain, and 
they felt that such composites should include measures of arthritis, enthesitis, dactylitis, 
inflammatory markers and patient global scores.  The failure to recommend inclusion of a psoriasis 
assessment is related to the low number of dermatology respondents.  The dermatologists chose 
skin measures as their top items but included the same measures as the rheumatologists 
(highlighted above) as their subsequent choices. 
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Patient survey – A total of 139 patients responded. Most reported that they see their physician every 
6 months for assessment, and the majority (84%) reported that their physician assessed only painful 
or problematic joints rather than a formal joint count.  Less than a quarter of patients are asked to 
complete any questionnaires at or prior to their appointment although 91% would be willing to do 
so if asked.  The most important domains of disease highlighted by the patients were pain (46%), 
joints (36%) and physical function. 
 
Discussion on measures 
Breakout groups were then convened to discuss the following measures: PASDAS, GRACE, CPDAI, 
DAPSA and the RAPID3 and 3-VAS scores.  The pros and cons of these measures highlighted by the 
breakout groups and subsequent discussions are shown in Table 2.  With the exception of DAPSA, 
the measures are composites covering multiple domains of PsA including peripheral arthritis, skin, 
dactylitis, enthesitis, axial disease, C-reactive protein (CRP), function and health related quality of life 
(HRQoL).  However no composite measure includes all of these.  Therefore for each measure, it is 
important to know which domains may not be fully assessed.  Some felt that measures of individual 
domains (eg DAPSA for peripheral arthritis) were optimal as disease activity could be quantified 
separately in each domain.  Any asynchronous flare in one domain (eg skin flare) would not impact 
the measurement of a potential improvement in joints.  The differential response of psoriatic 
disease domains may complicate interpretation of composite measures, as seen in the PRESTA trial 
where MSK outcomes were similar on two different doses of etanercept but a psoriasis dose 
response to treatment was observed(10).  These data show that the inclusion of skin disease in a 
composite psoriatic disease measure identifies a treatment effect in psoriatic disease as a whole 
despite no differential effect on MSK activity.  Some felt that composites covering multiple domains 
were optimal to quantify the overall burden of disease activity for each patient but clarified that 
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these should then be reported with their individual components to assess each domain as well as 
total scores. 
There was much discussion concerning the outcome measures in general but in particular about 
whether it is appropriate to include measures of physical function or HRQoL in a disease activity 
index.  These items may be considered measures of impact, influenced by cumulative damage as 
well as activity.  Whilst not ideal to have different measures, the varying feasibility for daily clinical 
practice and clinical trials was also discussed.   
The GRACE was felt to be a valuable composite but inclusion of the psoriasis area and severity index 
(PASI) was felt to be impractical for clinical usage.  Ideally the measure of skin disease should be 
feasible for non-dermatologists.  Adaptation of the GRACE measure with a simpler skin tool to 
replace the PASI may help but this would require further validation. 
RAPID3 is a commonly used generic measure of disease activity, particularly used in practice in the 
US.  Whilst the SLR showed preliminary validation in PsA, it was developed for RA and is focused on 
peripheral joint disease.  A modification with a psoriasis VAS (RAPID3Ps) has also been tested which 
may be more helpful in patients with significant skin disease. 
The 3VAS score was initially developed from the GRACE project but has not been widely published.  
It consists of an average of 3 VAS: patient skin, patient global and physician global.  This is quick and 
feasible but does not include any objective inflammation measures.  Whilst this is similar in 
feasibility to RAPID3, the inclusion of a physician global (which would indirectly require a physician’s 
examination) could be a benefit.  However there is little validation of this measure to date.  For both 
RAPID3 and 3VAS there was discussion about the potentially significant impact of comorbid 
fibromyalgia which may disproportionately affect these composites. 
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DAPSA is specifically a measure of peripheral arthritis without any inclusion of other domains.  
Several attendees commented that this was a good measure of peripheral arthritis, but separate 
assessment of skin disease and potentially other domains should be mandated alongside DAPSA to 
ensure a full assessment of PsA disease activity. 
Following the discussion, all attendees (rheumatologists, dermatologists and patient research 
partners) voted on the optimal composite scores for RCTs and clinical practice.  Each participant had 
up to five votes for the best measure for use in trials and up to five votes for the best measure in 
clinical practice.  These could be assigned to one measure, or distributed across them.  The outcome 
of the vote was spread across measures, with no single measure receiving a strong vote in favour for 
use in both settings (Figure 1).  For use in RCTs, PASDAS received the highest number of votes (n=40) 
followed by GRACE (n=28) and CPDAI (n=25) whilst for clinical practice, 3VAS received the highest 
number of votes (n=45) followed by DAPSA (n=26) and CPDAI (n=23).  A number of items were 
identified for the research agenda. 
At the end of this session, it was agreed that any measure can be used, as long as the patient’s 
disease is fully assessed and patient-reported outcomes are included in the evaluation. It is 
important to look at how existing composite measures could be modified for future use. 
 
Potential treatment targets 
Physician survey – The majority of HCPs (57%) believe that remission should be the optimal target of 
treatment with an alternative of low or minimal disease activity.  The most important factors that 
would influence HCPs when setting the treatment target include co-morbidities (81%), disease 
activity (79%) and patient goals (65%).  At present, 56% of HCPs report that they do treat-to-target in 
clinical practice and the three most popular targets utilised are MDA (32%), followed by DAS28 low 
disease activity (LDA) (10%) and DAS28 remission (9.5%).  Assessment of joints, health related 
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quality of life, and skin and nails, were most frequently mentioned as domains to include for a treat 
to target approach. 
Patient survey – Again the majority of patients (56%) agree that remission or alternatively MDA/LDA 
should be the treatment target and most patients (45%) defined ‘remission’ as the absence of 
disease or symptoms.  However the majority (61%) report that they have not discussed personal 
goals for managing their PsA with their rheumatologist and nearly 1 in 5 patients want their 
rheumatologist to listen to their concerns more. 
 
Discussion on targets 
The first discussion was the conceptual target of treatment.  The only treat to target study in PsA 
used MDA as the target (11), a measure of low disease activity rather than remission.  Despite this, 
the treatment arm had a higher rate of adverse events so it was discussed that the risks and benefits 
should be evaluated in each individual patient case.  In line with previous EULAR treatment 
recommendations (12) and the 2017 treat to target taskforce recommendations (13), the group 
unanimously agreed that remission should be the treatment target, but in certain circumstances, 
LDA/MDA is a reasonable alternative.  
Breakout groups were then convened to discuss the following targets: VLDA, MDA, modifications of 
MDA where some items are mandated and DAPSA remission/low disease activity.  The pros and cons 
of these measures highlighted by the breakout groups and subsequent discussions are shown in 
Table 3.   
Given the nature of the disease, the majority of attendees felt that for face validity, any measure of 
remission or low disease activity should assess multiple domains of disease, particularly peripheral 
arthritis and skin as these are the most prevalent domains.  Whilst rheumatologists tend to prioritise 
joints over skin when treating their patients with PsA, skin disease is highly important and impactful 
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to patients, with residual skin disease being associated with a poorer function and quality of life(14).  
When considering concepts such as remission the whole patient should be assessed.  
DAPSA can be used both as a measure of disease activity and a target.  However DAPSA is designed 
to measure peripheral arthritis with even the patient global VAS score asking about joint disease.  In 
some RCTs of biologics the levels of active skin disease and enthesitis of those in DAPSA remission 
are similar to VLDA(15).  However in studies of patients with significant baseline skin disease and 
recent real life clinic datasets, research has shown that patients in DAPSA remission can have 
significant levels of active skin disease with associated impact on HRQoL which goes against the face 
validity of such a measure as defining remission of psoriatic disease (16-19).  A potential solution 
would be to require physicians to assess multiple targets for individual measures such as peripheral 
arthritis and skin disease.  However there is a concern that physicians may not perform all 
assessments and therefore active disease would be missed.  Research on DAPSA also showed higher 
levels of residual disease activity than in VLDA/MDA possibly due to the nature of DAPSA as a 
summary score where one element can be high if the others are low(16-19).  
MDA/VLDA is a measure of disease state, not a measure of disease activity therefore if MDA is 
recommended as the target, a different composite of disease activity would still be required.  MDA 
and VLDA do not include a measure of acute phase reactants allowing calculation before blood 
results are known.  However it is recommended that acute phase reactants should be tested in 
addition to the clinical criteria aiming for normalisation in a chronic inflammatory disease(13).  The 
design of MDA is modular with each item assessed individually but as only 5 of the 7 criteria must be 
met for MDA, residual disease can occur in one domain, particularly skin as only one item measures 
skin disease directly.  This is not the case with VLDA (where all cutpoints must be met) or 
modifications that require the skin and/or joint items to be met.  Concern was raised about the 
inclusion of health assessment questionnaire (HAQ) as one of the items in MDA/VLDA.  This could 
potentially prevent patients from achieving VLDA despite adequate control of inflammatory disease 
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activity due to accumulated damage.  However in this case, the patient would achieve MDA as the 
alternative target. 
Following on from these discussions on the use of targets in PsA, attendees first voted on the 
domains that should be considered in a target.  The group unanimously agreed that when assessing 
a target of treatment, there should ideally be assessment of musculoskeletal disease, skin disease, 
and disease impact/HRQoL. 
There was agreement that both MDA and DAPSA had advantages and disadvantages and more 
research should be done. However, in the absence of data, it was agreed that the rheumatology 
community needs guidance on what to use now to encourage a treat-to-target approach. This was 
observed with DAS28 in RA, which was initially not liked but is now widely accepted. Therefore a 
motion was proposed that “the group at present recommends a target of treatment as VLDA 
(remission), or MDA 5/7 as an alternative low/MDA”.  This was not unanimously supported, there 
were 21 votes in favour, 2 against and 1 abstention.   
 
Post meeting survey 
Physician survey – A total of 115 HCPs responded to the second survey, the majority (77%) 
rheumatologists.  Most supported the development of composites but agreed with the advantages 
and disadvantages listed.  Overall the RAPID3 and 3VAS were felt to be quick and feasible but not 
comprehensive enough with no objective measures included.  DAPSA was feasible but only included 
assessment of peripheral arthritis and was felt to be more appropriate for polyarticular disease.  
GRACE, PASDAS and CPDAI were felt to be comprehensive but less feasible for routine practice.  The 
balance between inclusion of key domains but without being time consuming was felt to be key.  
Less than 10 minutes, or ideally less than 5 minutes was felt to be reasonable for clinical practice.  
CPDAI was the highest ranked (6.4/10) for use in clinical practice but all scores were ranked between 
4.5 and 6.5.  For RCTs, CPDAI, PASDAS and GRACE were felt to be the most appropriate scoring 6.7, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
6.4 and 6.6 out of 10, with the rest less popular.  The vast majority (93%) supported the decision 
from the meeting that all measures should be studied further and data should be collected to allow 
comparison. 
The specific issue of the inclusion of HAQ in some measures was also addressed.  The majority felt 
that HAQ could (48%) or should (13%) be included in composites.  Most recognised that HAQ could 
be influenced by domains other than disease activity but that “whilst it is affected by damage, even 
in established disease it frequently shows change and can be useful to measure”.   
The majority of HCPs (92%) supported the recommendation that the conceptual target should be 
remission or alternatively MDA/LDA.  Some highlighted that there is not yet evidence for additional 
benefits of remission over MDA and that there may be a risk of increased treatment burden.  92% 
support the fact that the target should include MSK and skin disease, and 90% support the inclusion 
of HRQoL as well.  For the target to be used, 90% supported the recommendation of VLDA and/or 
MDA as the treatment target.  
Patient survey – A total of 64 patients responded the post-meeting survey. The majority (72%) 
supported the recommendation that the target should encompass MSK disease, skin disease and 
HRQoL.  They also specifically mentioned fatigue, enthesitis and physical function as key domains.  
The vast majority (90%) supported the concept of remission or alternatively LDA as a target and the 
recommendation for the use of VLDA/MDA (77%). 
 
Research Agenda 
Throughout the meeting, items for the research agenda were identified and noted.  Whilst a 
significant amount of data is available for the composites following recent research, as identified by 
the SLR, there is still a lot to understand about these measures.  Many composite measures were 
developed without substantial patient involvement and this should be addressed in future research.  
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Recent research has highlighted that concomitant fibromyalgia impacts on all disease outcome 
measures and this must be considered.  For specific measures a variety of validation data is missing.  
In particular, there has been very little analysis on the 3VAS measure and this needs a lot more 
validation.  For some of the composite measures, additional data is particularly required on the 
validity of the cut points as potential targets such as those for PASDAS and CPDAI. 
A number of research agenda items related to less well studied domains including axial disease, 
fatigue and nail disease.  Whilst many measures include a patient global, there is a wide variety of 
the wordings used in these composites which would benefit from further analysis and 
standardisation.  There were also a number of potential modifications that were suggested for the 
existing composites.  For the multi-domain measures the majority of modifications were related to 
simplification (eg BSA or PGA x BSA substituted for PASI) or substitution of HRQoL or physical 
function measures.  For DAPSA, there was interest in studying DAPSA alongside a skin measure, 
particularly when considering it as a target.  Particularly for potential targets, additional data directly 
comparing measures, and their concordance/discordance will be valuable to understand them 
further. 
 
Summary 
Within the OMERACT framework for developing a core outcome measurement set for PsA(2), a 
consensus meeting is reported which established current practice using physician and patient 
surveys, discussed current SLRs to establish evidence, debated the advantages and disadvantages of 
the different measures and made recommendations on the use of composite measures and clinical 
targets.  While a single composite measure was not chosen, a research agenda was established to 
aid in this.  For targets, there was agreement on the conceptual definition of the target (remission or 
alternatively low/minimal disease activity), domains that should be considered (MSK, skin and 
HRQoL) and a proposed target of VLDA or MDA for current practice. 
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Table 1: Domains included in the composite measures discussed 
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PASDAS √  √ √  √ √  √  √ 
GRACE √ √  √ √    √ √  
CPDAI    √ √ √ √ √ √ √  
DAPSA √ √  √       √ 
3VAS √  √ √    
RAPID3 √ √        √  
MDA/VLDA √ √  √ √ √  √  
 
3VAS – 3 visual analogue scores, CPDAI – composite psoriatic disease activity index, DAPSA – disease 
activity in PsA, GRACE – GRAPPA composite score, MDA – minimal disease activity, PASDAS – PsA 
disease activity score, RAPID3 – routine assessment of patient index data 3, VLDA – very low disease 
activity 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2: Advantages and disadvantages of composite disease activity measures from breakout and 
discussions. 
Measures Advantages Disadvantages 
DAPSA • Captures arthritis specifically
(different drugs act on different 
aspects of PsA disease) 
• Can be used with or without CRP 
• Continuous measure 
• States response 
• Responsiveness 
• Relatively simple measure; easy 
application in practice 
• Feasibility (calculation and 
conduct) 
• Validated cut-points 
• Uses 66/68 joint count 
 
• No skin/dactylitis/ 
enthesitis/nails/fatigue 
• Does not capture totality of 
psoriatic disease (‘PRO’) 
• Fatigue (depression) 
• FMS influence 
• Arthritis global rather than true 
global VAS 
• Face validity lacking as other 
domains of PsA not assessed 
• Composite of articular disease 
only 
 
PASDAS • Comprehensive 
• Captures many dimensions of the 
disease 
• Responsive 
• Patient perspective 
• PGA/ PtGA includes skin 
• Can give individual scores 
• Includes enthesitis/dactylitis 
• Good cut-off validity 
• Escapes from RA paradigm 
• PsA specific 
 
• Not transparent 
• Needs computer to calculate 
• Not currently used much 
• No specific skin measure 
• No specific axial component 
• Fatigue*/pain* are not 
captured 
• No specific participations* or 
functions; functions as 
outcome measures is old and 
outdated 
• No reliability data 
• SF-36 has disadvantages (not 
disease-specific, cost, etc.) 
*Important outcomes for patients 
 
3VAS • No blood test required 
• Patient-centric 
• Simple, speedy and feasible 
• Includes skin disease 
• Potential to add nail 
disease 
• Physician global (but mandates a 
joint count) 
• Fits into PASDAS 
• Potential to add pain to global 
assessment, following definition 
 
• Too easy to manipulate 
• Dangerous for decision making 
• No APRs 
• Effect of patient global/patient 
pain – not disease activity 
• Not specific to enthesitis or 
axial disease 
• No objective measures 
• No mandated joint count 
RAPID3 • Includes pain 
• Can be modified to measure skin 
using RAPID3Ps 
• Very quick and feasible 
• Includes HAQ which may reflect 
damage as well as activity 
• May be forced to pay for use 
• No objective measures 
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• Only generic disease measure • Includes patient measures but 
no physician global 
assessments 
 
GRACE • PsA specific 
• Has face validity 
• Feasible 
• Patient-reported with additional 
measures of joint counts 
• Has components from clinical 
trials (joint count, PASI) 
• Feasible to translate into clinical 
practice 
 
• No APRs
• Includes HAQ 
• Includes PASI, which has 
limitations 
• Not as feasible for clinical 
practice 
CPDAI • Skin included and other relevant 
domains 
• Modular and adaptable to reflect 
changes in disease assessment 
• Computerised version (MOPsA) 
• Captures differential response 
• Intuitive; makes sense 
• Does not involve blood tests 
• Preserves mild/moderate/severe 
disease 
• No pain/fatigue/patient 
global/APRs 
• Cut-offs for skin disease 
• Does not assess nail disease 
• Time consuming, so difficult to 
do in clinic but MOPsA helps 
(can complete in 6 minutes) 
3VAS – 3 visual analogue scores, CPDAI – composite psoriatic disease activity index, DAPSA – disease 
activity in PsA, GRACE – GRAPPA composite score, PASDAS – PsA disease activity score, RAPID3 – 
routine assessment of patient index data 3 
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Table 3: Advantages and disadvantages of PsA target measures from breakout and discussions. 
Measures Advantages Disadvantages 
MDA/VLDA • Feasible in practice
• Simple to perform (no 
calculations) 
• Derived from patient data 
• Includes global assessment and 
pain 
• Strong evidence with treat-to-
target TICOPA 
• Responsive to change, correlates 
to damage, sustains over time 
• Correlates with patient opinion 
(PsAID) 
• Modular so no items can score 
too highly 
• MDA matches well with PASS & 
PsAID PASS 
• Includes 
joints/skin/enthesitis/PROs 
• Does not require CRP for 
calculation 
 
• HAQ may prevent VLDA 
• Dermatology threshold could 
be lower in line with 
dermatologist recs (BSA ≤1%) 
• Heterogeneous in terms of 
response 
• Binary, not a continuous 
activity measure 
• MDA can have some active 
skin and joint disease activity 
• Possibility of overtreatment 
as VLDA may be difficult to 
achieve  
• Nails not included 
• No specific measure of axial 
disease 
• Add impact to target, e.g. 
PsAID 
• Does not include CRP, so 
should be done separately 
MDA 
modifications 
• Emphasises skin and/or joints 
domains 
• MDA composite forces domain 
look 
• Target not a measure 
• Avoids active skin disease if this 
domain is required (otherwise it 
can be missed despite MDA) 
• Includes HAQ (Concern over 
whether this may reflect 
damage not activity, could 
not be removed/replaced 
without further research) 
• Consider others (i.e. PFI-10, 
SF-36, PsAID, PsAQoL) 
• Dermatology threshold could 
be lower in line with 
dermatologist  recs (BSA 
≤1%) 
• Does not include PROs for 
skin 
 
DAPSA 
remission/LDA 
• Feasible in practice
• Simple to perform (easy 
calculation) 
• Includes global assessment and 
pain 
• Exclusion of HAQ is regarded by 
some as a positive 
• Responsive to change 
• Correlates to damage, states 
disease activity, sustains over 
time 
• Not Boolean restricted 
• Psoriatic disease vs PsA vs skin 
• Misses skin and nails 
• Does not measure axial 
disease or enthesitis 
• Exclusion of HAQ is regarded 
by some as a negative 
• No data on patient opinion of 
remission/LDA 
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disease 
• Includes CRP 
BSA – body surface area, DAPSA – disease activity in PsA, HAQ – health assessment questionnaire, 
LDA – low disease activity, MDA – minimal disease activity, PASS – patient acceptable symptom 
state, PRO – patient reported outcome, PsAID – PsA impact of disease score, TICOPA – tight control 
of psoriatic arthritis study, VLDA – very low disease activity 
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Table 4: Research Agenda 
Additonal 
validation 
data 
• 3VAS 
• CPDAI 
• GRACE 
• PASDAS 
• CPDAI and/or PASDAS as a target 
General • What treat-to-target information measures do trials or regulatory 
companies (such as the FDA) need, as these may need to be included in 
composite measures 
• Is it possible to use only the spine-related questions from the BASDAI 
questionnaire 
• Fatigue to be assessed in clinical practice, as it is not currently assessed 
as a single domain in any composite measure 
• How nail assessment be added or captured in existing measures 
• How to deal with fibromyalgia as it affects all of these tools 
Importance of 
skin disease 
• If residual skin disease is allowed within a target, how does this impact on 
the patient? 
• In different populations how do standard MDA and modifications 
requiring skin/joints compare? 
• Validation of more feasible proxies for PASI such as PGA x BSA 
Potential 
modifications 
CPDAI
• Can CPDAI be adapted to include other modules 
• Can DAPSA be used for the joint portion 
• SPARCC to LEI conversion 
• Nails 
• What if you use the spine measures and not BASDAI 
• Should PASI be substituted with BSA 
• Could this be simplified 
• Could other modules for CPDAI be added eg life impact 
DAPSA 
• The PCA cohort did not include patients with more severe skin disease – 
repeat PCA in a cohort with more skin disease 
• Does skin pain factor into the pain VAS 
• Should global be expanded to include skin and arthritis 
• What would a target that includes DAPSA + skin, or DAPSA + skin and 
nails assessment look like and how would it behave psychometrically 
GRACE 
• Can GRACE be adapted to include BSA 
• Can PsAQoL be substituted with PsAID in GRACE 
RAPID3 
• Can HAQ be substituted with a skin assessment in RAPID3 
MDA 
• Switch out HAQ for PSAID or other PROs 
• Add impact/PSAID 
• Add nails, or nail VAS 
• BSA target 1% (though 3% acceptable) - should this be changed for VLDA 
 
Global • Does the PtGA capture the correct domains 
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assessment • What happens when the definitions of PtGA are changed in different 
measures 
• Retrospective analysis of different approaches to carrying out global 
assessments 
HAQ • How are composite scores affected when HAQ is excluded 
o How does this changes the psychometric properties of the other 
outcomes 
• If physical outcomes are necessary to include in composite measures, is 
HAQ the most appropriate measure 
• Can a new outcome measure for physical function be used instead of 
HAQ 
• Can HAQ be substituted with PsAID 
• Can HAQ be excluded from MDA, and what difference does this make 
Comparing 
remission 
• What prevents a person from getting to MDA/VLDA 
• What prevents a person from achieving DAPSA remission/LDA 
• Among the DAPSA remission group, what is preventing someone from 
getting VLDA? 
3VAS – 3 visual analogue scores, BASDAI – Bath ankylosing spondylitis disease activity index, BSA – 
body surface area, CPDAI – composite psoriatic disease activity index, DAPSA – disease activity in 
PsA, GRACE – GRAPPA composite score, HAQ – health assessment questionnaire, LEI – Leeds 
enthesitis index, MDA – minimal disease activity, PASDAS – PsA disease activity score, PASI – 
psoriasis area and severity index, PCA – principle component analysis, PGA – physician global 
assessment, PRO – patient reported outcome, PsAID – PsA impact of disease, PsAQoL – PsA quality 
of life, PtGA – patient global assessment, RAPID3 – routine assessment of patient index data 3, 
SPARCC – spondyloarthritis research consortium of Canada, VAS – visual analogue score, VLDA – very 
low disease activity 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure 1: Outcome of a weighted vote for outcome measures in clinical practice and clinical trials 
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